BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19661205)

  • 1. Comparison between the Abbott RealTime High Risk HPV assay and the Hybrid Capture 2 assay for detecting high-risk human papillomavirus DNA in cervical specimens.
    Kaliterna V; Židovec Lepej S; Vince A
    J Med Microbiol; 2009 Dec; 58(Pt 12):1662-1663. PubMed ID: 19661205
    [No Abstract]   [Full Text] [Related]  

  • 2. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test.
    Poljak M; Kovanda A; Kocjan BJ; Seme K; Jancar N; Vrtacnik-Bokal E
    Acta Dermatovenerol Alp Pannonica Adriat; 2009 Sep; 18(3):94-103. PubMed ID: 19784522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Abbott RealTime High Risk HPV and Hybrid Capture 2 for the detection of high-risk HPV DNA in a referral population setting.
    Venturoli S; Leo E; Nocera M; Barbieri D; Cricca M; Costa S; Santini D; Zerbini M
    J Clin Virol; 2012 Feb; 53(2):121-4. PubMed ID: 22115872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Cobas 4800 Human Papillomavirus test against a combination of the Amplicor Human Papillomavirus and the Linear Array tests for detection of HPV types 16 and 18 in cervical samples.
    Martínez SB; Palomares JC; Artura A; Parra M; Cabezas JL; Romo JM; Martín-Mazuelos E
    J Virol Methods; 2012 Mar; 180(1-2):7-10. PubMed ID: 22197189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-risk HPV detection and concurrent HPV 16 and 18 typing with Abbott RealTime High Risk HPV test.
    Tang N; Huang S; Erickson B; Mak WB; Salituro J; Robinson J; Abravaya K
    J Clin Virol; 2009 Jul; 45 Suppl 1():S25-8. PubMed ID: 19651365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the clinical performances of the AdvanSure HPV Screening Real-Time PCR, the Abbott Real-Time High-Risk HPV Test, and the Hybrid Capture High-Risk HPV DNA Test for Cervical Cancer Screening.
    Chung HS; Hahm C; Lee M
    J Virol Methods; 2014 Sep; 205():57-60. PubMed ID: 24814874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
    Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
    J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analytical performance of Cervista HPV 16/18 genotyping test for cervical cytology samples.
    Bartholomew DA; Luff RD; Quigley NB; Curtis M; Olson MC
    J Clin Virol; 2011 May; 51(1):38-43. PubMed ID: 21376660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears.
    Cuzick J; Ambroisine L; Cadman L; Austin J; Ho L; Terry G; Liddle S; Dina R; McCarthy J; Buckley H; Bergeron C; Soutter WP; Lyons D; Szarewski A
    J Med Virol; 2010 Jul; 82(7):1186-91. PubMed ID: 20513082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the analytical and clinical performances of Abbott RealTime High Risk HPV, Hybrid Capture 2, and DNA Chip assays in gynecology patients.
    Park S; Kang Y; Kim DG; Kim EC; Park SS; Seong MW
    Diagn Microbiol Infect Dis; 2013 Aug; 76(4):432-6. PubMed ID: 23791386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Methods of HPV detection in exfoliated cells and tissue specimens approved by the United States Food and Drug Administration].
    Zhao CQ; Yang HT; Tian ZD; Huang WB
    Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):855-7. PubMed ID: 23324242
    [No Abstract]   [Full Text] [Related]  

  • 12. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.
    Zhao X; Wu Q; Wang X; Fu Y; Zhang X; Tian X; Cheng B; Lu B; Yu X; Lan S; Lu W; Ma D; Cheng X; Xie X
    Clin Microbiol Infect; 2018 Dec; 24(12):1322-1327. PubMed ID: 29518562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Enhanced molecular techniques for the diagnosis of human papillomavirus infections].
    Ursu RG; Onofriescu M; Nemescu D; Iancu LS
    Rev Med Chir Soc Med Nat Iasi; 2009; 113(4):1205-10. PubMed ID: 20191900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papillomavirus detection using the Abbott RealTime high-risk HPV tests compared with conventional nested PCR coupled to high-throughput sequencing of amplification products in cervical smear specimens from a Gabonese female population.
    Moussavou-Boundzanga P; Koumakpayi IH; Labouba I; Leroy EM; Belembaogo E; Berthet N
    Virol J; 2017 Dec; 14(1):241. PubMed ID: 29268766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus multiplex ligation-dependent probe amplification assay for the assessment of viral load, integration, and gain of telomerase-related genes in cervical malignancies.
    Theelen W; Litjens RJ; Vinokurova S; Haesevoets A; Reijans M; Simons G; Smedts F; Herrington CS; Ramaekers FC; von Knebel Doeberitz M; Speel EJ; Hopman AH
    Hum Pathol; 2013 Nov; 44(11):2410-8. PubMed ID: 23968641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of GeneFinder human papillomavirus (HPV) Liquid Beads Microarray PCR Kit and Hybrid Capture 2 Assay for Detection of HPV Infection.
    Ko K; Kwon MJ; Lee EH; Woo HY; Park H
    J Clin Lab Anal; 2017 Mar; 31(2):. PubMed ID: 27387091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus genotypes in women with invasive cervical cancer with and without human immunodeficiency virus infection in Botswana.
    Tawe L; MacDuffie E; Narasimhamurthy M; Wang Q; Gaseitsiwe S; Moyo S; Kasvosve I; Shin SS; Zetola NM; Paganotti GM; Grover S
    Int J Cancer; 2020 Mar; 146(6):1667-1673. PubMed ID: 31325316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPV prevalence and type-distribution in cervical cancer and premalignant lesions of the cervix: A population-based study from Northern Ireland.
    Anderson LA; O'Rorke MA; Wilson R; Jamison J; Gavin AT;
    J Med Virol; 2016 Jul; 88(7):1262-70. PubMed ID: 26680281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot analytic study of a research-level, lower-cost human papillomavirus 16, 18, and 45 test.
    Yang HP; Walmer DK; Merisier D; Gage JC; Bell L; Rangwala S; Shrestha N; Kobayashi L; Eder PS; Castle PE
    J Virol Methods; 2011 Sep; 176(1-2):112-4. PubMed ID: 21640138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human papillomavirus (HPV) E6/E7 mRNA as a triage test after detection of HPV 16 and HPV 18 DNA.
    Perez Castro S; Iñarrea Fernández A; Lamas González MJ; Sarán Diez MT; Cid Lama A; Alvarez Martín MJ; Pato Mosquera M; López-Miragaya I; Estévez N; Torres Piñón J; Oña Navarro M
    J Med Virol; 2013 Jun; 85(6):1063-8. PubMed ID: 23588733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.